Results 201 to 210 of about 112,622 (301)

DNA Methylation in Ovarian and Endometrial Cancers: Predictive and Mechanistic Roles in PARP Inhibitor and ICI Response. [PDF]

Cancer Sci
Kitamura S, Taguchi A, Tamai K, Yamamoto Y, Duong AQ, Yoshimoto D, Mori A, Ishizaka A, Tsuchimochi S, Sone K, Kawazu M, Oda K, Hirota Y.   +12 more
europepmc   +1 more source

Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol

International Journal of Cancer, Volume 158, Issue 6, Page 1617-1627, 15 March 2026.
What's new? PARP inhibitors are effective in patients with inactivating alterations in the BRCA1/2 genes across tumor types. However, the efficacy of PARP inhibitors in patients with other inactivated homologous recombination repair genes remains unclear. This knowledge gap and discrepancies in EMA/FDA approvals highlight the need for better biomarkers.
Ilse A. C. Spiekman, Niven Mehra, Laurien J. Zeverijn, Birgit S. Geurts, Karlijn Verkerk, Soemeya F. Haj Mohammad, Vincent van der Noort, Paul Roepman, Wendy W. J. de Leng, Anne M. L. Jansen, Addy C. M. van de Luijtgaarden, Theo van Voorthuizen, Tineke E. Buffart, Hans Gelderblom, Emile E. Voest, Henk M. W. Verheul   +15 more
wiley   +1 more source

PARP Inhibitor Olaparib and Its Combination Therapy in Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-analysis. [PDF]

Eur Urol Open Sci
Li Y, Li Z, Lu H, Shi P, Liu Y, Liu L, Chen K.   +6 more
europepmc   +1 more source

Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling—The CATCH experience

International Journal of Cancer, Volume 158, Issue 6, Page 1675-1689, 15 March 2026.
What's new? CATCH is a prospective precision oncology registry trial that harnesses whole‐genome/exome‐ and RNA‐sequencing to enable actionable biomarker detection in metastatic breast cancer patients of any subtype. The data of the first 412 consecutive patients with completed follow‐up in this real‐world, single‐center patient cohort provide robust ...
Mario Hlevnjak, Sabine Heublein, Verena Thewes, Lukas Wagener, Constantin Pixberg, Carlo Fremd, Laura Michel, Christian Maurer, Lars Buschhorn, Nicola Dikow, Fangyoumin Feng, Stefan Fröhling, Christel Herold‐Mende, Steffen Hirsch, Chen Hong, Daniel Hübschmann, Lena Jassowicz, Polina Kozyulina, Katrin Pfütze, Richard F. Schlenk, Hans‐Peter Sinn, Katharina Smetanay, Christoph Springfeld, Albrecht Stenzinger, Celina Wagner, Stephan Wolf, Andreas Trumpp, Dirk Jäger, Oliver Zivanovic, Marc Zapatka, Andreas Schneeweiss, Peter Lichter   +31 more
wiley   +1 more source

Therapeutic Potential of Metal-Based and PARP Inhibitor Chemotherapy for <i>BRCA1</i>-Associated Triple-Negative Breast Cancer. [PDF]

Int J Mol Sci
Ratanaphan A.
europepmc   +1 more source

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 618-628, March 2026.
We present model‐informed selection of the recommended dose for expansion (RDE) of investigational oral ATR inhibitor tuvusertib, by integrating clinical pharmacokinetics (PK), pharmacodynamics (PD), and safety data from DDRiver Solid Tumors 301 trial Part A1 (NCT04170153).
Jatinder Kaur Mukker, Paul Matthias Diderichsen, Farina Hellmann, Timothy A. Yap, Ruth Plummer, Anthony W. Tolcher, Johann S. de Bono, Ioannis Gounaris, Zoltan Szucs, Astrid Zimmermann, Irina Kareva, Jayaprakasam Bolleddula, Annick Seithel‐Keuth, Giuseppe Locatelli, Marta Enderlin, Christine Hicking, Anup Zutshi, Wei Gao, Rainer Strotmann, Lisa Benincosa, Karthik Venkatakrishnan   +20 more
wiley   +1 more source

Characterization of Parthanatos in Breast Cancer: Implications for Prognosis and PARP Inhibitor Resistance. [PDF]

Bioengineering (Basel)
Tang J, Liu Q, Du W, Chen L, Qi F, Zhang R, Hoang BH, Geller DS, Yang R, Wang J, Hu L.   +10 more
europepmc   +1 more source

Bioactive Phytochemical Compounds in Medicago sativa L. (Alfalfa): A Systematic Review of Biological Properties and Therapeutic Relevance in Nutraceutical and Functional Food Implications

Food Frontiers, Volume 7, Issue 2, March 2026.
ABSTRACT Medicago sativa L. (alfalfa) harbors a remarkably diverse reservoir of bioactive secondary metabolites. Flavonoids, isoflavones, and triterpenoid saponins dominate its bioactivity landscape, driving potent antioxidant, anti‐inflammatory, antimicrobial, estrogenic, hypolipidemic, and cytotoxic actions through redox modulation, membrane ...
Parham Joolaei Ahranjani, Hamid Rashidi Nodeh, Zahra Esfandiari, Giovanna Ferrentino   +3 more
wiley   +1 more source

PARP inhibitor resistance in IDH1-mutant cancers due to loss of end protection factors, 53BP1 and REV7. [PDF]

NAR Cancer
Colón-Ríos DA, Dow J, Krysztofiak A, Liu Y, Rogers FA, Glazer PM.   +5 more
europepmc   +1 more source

Drastic Response to Olaparib in a Patient With Metastatic Castration‐Resistant Prostate Cancer Harboring BRCA2 Alterations and Near‐Threshold Tumor Mutational Burden

IJU Case Reports, Volume 9, Issue 2, March 2026.
ABSTRACT Introduction BRCA2 alterations and high tumor mutational burden (TMB‐H) are responsible for prostate cancer; however, their co‐occurrence is uncommon, and evidence for PARP inhibition in the castration‐sensitive setting remains limited. We describe a case of metastatic castration‐resistant prostate cancer (CRPC) harboring both biomarkers ...
Kotaro Yokota, Takeo Kosaka, Tatsuaki Daimon, Shinnosuke Fujiwara, Kohei Nakamura, Hiroshi Nishihara, Mototsugu Oya   +6 more
wiley   +1 more source